In Depth 9 Aug 2023
Meet the startup working to help treat a rare pediatric cancer
Nearly 50% of the children diagnosed with neuroblastoma are considered high-risk, where the tumor has spread, making surgery no longer a viable treatment option. Owing to this stark statistic, the disease is quite difficult to treat. But there might be light at the end of the tunnel. U.K.-based Renaissance Pharma’s drug candidate, which has shown […]
